GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK70) » Definitions » 3-Year EPS without NRI Growth Rate

Conduit Pharmaceuticals (FRA:ZK70) 3-Year EPS without NRI Growth Rate : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Conduit Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was €-5.96.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Competitive Comparison of Conduit Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Conduit Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conduit Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Conduit Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Conduit Pharmaceuticals  (FRA:ZK70) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Conduit Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4995 Murphy Canyon Road, Suite 300, San Diego, CA, USA, 92123
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines